Skip to main content

Dr. John M. Strother, M.D

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
26
In the NPI registry since
2006
Medicare patients seen, 2024
631

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2000Medical school: Pennsylvania State University College of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    OR license MD23542
  • Hematology (Internal Medicine) Physician
    OR license MD22929

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
631
Services billed
134,026
Patients’ average age
73
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, oxaliplatin, 0.5 mg15,40012
Injection, fosaprepitant, 1 mg13,20027
Injection, bortezomib, 0.1 mg2,98311
Injection, dexamethasone sodium phosphate, 1 mg1,61257
Injection, palonosetron hcl, 25 mcg1,00035
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count747218
Blood test, comprehensive group of blood chemicals706208
Injection, ondansetron hydrochloride, per 1 mg65632
Established patient office or other outpatient visit, 30-39 minutes590253
Insertion of needle into vein for collection of blood sample520175

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 14 companies reported 26 payments worth $668 in total to this clinician.

By type
Food and Beverage$481
Travel and Lodging$167
Education$20.00

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Oct 26, 2025Beone Medicines USA, Inc.
Oct 26, 2025
Travel and Lodging
travel to Salem, Mexico
$72.00
Oct 26, 2025Beone Medicines USA, Inc.
Oct 26, 2025
Travel and Lodging
travel to Salem, Mexico
$47.60
Oct 29, 2025Beone Medicines USA, Inc.
Oct 29, 2025
Travel and Lodging
travel to Salem, Mexico
$47.60
Mar 6, 2025Aveo Pharmaceuticals, Inc.
Mar 6, 2025
Education
FOTIVDA · Oncology · in-kind
$20.00

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Oregon →

Industry-funded research

Named as a principal investigator on 6 industry-funded studies in 2025, from 6 companies. The companies reported $230,292 in research payments for these studies, mostly to the institutions running them.

  • A Randomized, Open label, Phase 3 Study of MK-2870 in Combination with Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer with PD…
    Merck Sharp & Dohme LLC
  • A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
    Beone Medicines Ltd. · Recruiting · NCT07043400
  • A phase 3, randomized, double-blind, placebo-controlled study of LY4064809 combined with a CDK4/6 inhibitor and endocrine therapy in adults with hr+, HER2- advanced breast cancer with a PIK3CA mutation who received no…
    Eli Lilly and Company
  • A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide and Dexamethasone VRd in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem …
    Janssen Research & Development, LLC
  • Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatm…
    Celgene Corporation
  • BNT327
    BioNTech SE

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Salem

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 7, 2023), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1518922111. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.